c-Met Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S1068	PF-02341066 (Crizotinib)	Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Signal Transduct Target Ther, 2025, 10(1):124 Cell Rep Med, 2025, S2666-3791(25)00102-8 Cell Death Differ, 2025, 10.1038/s41418-025-01510-x
S1112	SGX-523	SGX-523 is a selective Met (c-Met) inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.	Stem Cell Res Ther, 2025, 16(1):526 iScience, 2025, 28(2):111708 Cancer Immunol Immunother, 2025, 74(2):58
S1070	PHA-665752	PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.	Cell Death Dis, 2025, 16(1):76 Aging Cell, 2025, e70042. Biochim Biophys Acta Mol Cell Res, 2025, 1872(7):120001
S1111	Foretinib	Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.	J Microbiol, 2025, 63(2):e2409001 Int J Mol Sci, 2023, 24(1)757 Biol Open, 2023, 12(8)bio059994
S2788	Capmatinib (INC280)	Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.	Mol Cancer, 2025, 24(1):272 Cell Rep Med, 2025, 6(9):102335 J Biomed Sci, 2025, 32(1):94
S1080	SU11274	SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. This compound induces autophagy, apoptosis and cell cycle arrest.	Cell Death Dis, 2025, 16(1):76 World J Exp Med, 2025, 15(2):100443 Cancer Cell Int, 2024, 24(1):43
S5190	Crizotinib hydrochloride	Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell-based assays, respectively. Crizotinib hydrochloride is also a potent ROS1 inhibitor with Ki less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Cancer Discov, 2023, 13(3):598-615 Nat Commun, 2023, 14(1):2829 Cancer Res Commun, 2023, 3(4):659-671
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cell Rep, 2025, 44(8):116096 Front Immunol, 2025, 16:1601420 Endocrinology, 2025, 166(11)bqaf146
S1114	JNJ-38877605	JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.	Int J Mol Sci, 2025, 26(5)2308 Gastric Cancer, 2024, 10.1007/s10120-024-01537-y Int J Mol Sci, 2023, 24(9)8086
S2753	Tivantinib	Tivantinib is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. This compound induces a G2/M arrest and apoptosis.	Acta Neuropathol, 2024, 147(1):44 Eur J Cell Biol, 2024, 103(4):151457 Elife, 2023, 12e79432
S1094	PF-04217903	PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.	Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003 Neoplasia, 2019, 22(1):1-9 Sci Rep, 2019, 9(1):606
S7067	Tepotinib (EMD-1214063)	Tepotinib is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib (EMD 1214063) induces autophagy. Phase 1.	J Biomed Sci, 2025, 32(1):94 Cell Oncol (Dordr), 2025, 10.1007/s13402-025-01097-y Lung Cancer, 2025, 201:108415
S7674	Savolitinib (AZD6094)	Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.	Cell Death Discov, 2025, 11(1):372 PLoS One, 2025, 20(9):e0329706 EXCLI J, 2024, 23:1287-1302
S1361	MGCD-265 analog	MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.	Cell & Bioscience, 2024, 109 Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492
S7014	Merestinib (LY2801653)	Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. This compound also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.	Mol Oncol, 2025, 19(8):2366-2387 Molecular Oncology, 2025, 2366-2387 NPJ Breast Cancer, 2024, 10(1):65
S2859	Golvatinib (E7050)	Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, respectively. This compound does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM) and is currently in Phase 1/2 trials.	Int J Mol Sci, 2023, 24(11)9606 International Journal of Molecular Sciences, 2023, 9606 International Journal of Molecular Sciences, 2022, 14884
S2774	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2.	Mol Carcinog, 2021, 60(7):481-496 G3 Genes\|Genomes\|Genetics, 2021, jkab265 G3 (Bethesda), 2021, 11(10)jkab265
E1340	Glesatinib	Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. This compound counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).	Protein & Cell, 2019, 161-177 Translational Cancer Research, 2019, 2425-2438 Transl Cancer Res, 2019, 8(6):2425-2438
S8167	AMG 337	AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the Met (c-Met) receptor with an IC50 of 1 nM.	Journal of Biological Chemistry, 2022, 101630 J Biol Chem, 2022, S0021-9258(22)00070-9 Cancer Cell, 2019, 36(1):35-50
S7669	NPS-1034	NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.	Nat Commun, 2023, 14(1):4162 J Med Chem, 2021, 64(6):3165-3184 Sci Rep, 2021, 11(1):19667
S2201	BMS-794833	BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.	Cell Stem Cell, 2025, 32(11):1671-1690.e13 Cancer Res, 2021, canres.1428.2021
S9308	Pulsatilla saponin D	Pulsatilla saponin D (SB365), isolated from the root of Pulsatilla koreana, targets c-Met and exerts antiangiogenic and antitumor activities.	Journal of Pharmacy and Pharmacology, 2025, 511–523 J Pharm Pharmacol, 2025, rgaf006
S2761	NVP-BVU972	NVP-BVU972 is a selective and potent Met (c-Met) inhibitor with IC50 of 14 nM.	PLoS Biol, 2021, 19(5):e3001263
S8404	S49076	S49076 is a novel, potent inhibitor of Met (c-Met), AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.	Mol Brain, 2020, 4;13(1):66
S6762	Bozitinib	Bozitinib (PLB-1001) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. This compound selectively inhibits MET-altered tumor cells in preclinical models.	Commun Biol, 2025, 8(1):134
S8676	Glumetinib	Glumetinib is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. This compound has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.	Cell Death Dis, 2024, 15(8):600
S1316	AMG-208	AMG 208 is a highly selective dual c-Met and RON inhibitor with IC50 of 9 nM for c-Met.
S2747	AMG-458	AMG 458 is a potent c-Met inhibitor with K_i of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
S0540	BAY-474	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
S8854	JNJ-38877618(OMO-1)	A potent, highly selective, orally bioavailable Met (c-Met) kinase inhibitor, JNJ-38877618 (OMO-1) exhibits binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant Met (c-Met) (2 and 3 nM IC50).
S9620	Elzovantinib (TPX-0022)	Elzovantinib (TPX-0022, CSF1R-IN-2) is a potent inhibitor of MET/CSF1R/SRC with enzymatic kinase inhibition IC50s of 0.14 nM, 0.71 nM and 0.12 nM, respectively. TPX-0022 modulates the tumor immune microenvironment in preclinical models.
S6870	Ningetinib	Ningetinib (CT-053, DE-120, CT053PTSA) is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. This compound exhibits antitumor activity.
S0361	AMG-1	AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively.
S7564	SAR125844	SAR125844 is a potent intravenously active and highly selective Met (c-Met) kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
E4914	Cabozantinib hydrochloride	Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
E0142	XL092	XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.
S1119	Cabozantinib (XL184)	A potent VEGFR2 inhibitor with IC50 of 0.035 nM, Cabozantinib (XL184) also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. It induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.	Nat Commun, 2025, 16(1):509 Cell Death Differ, 2025, 10.1038/s41418-025-01510-x Cell Death Dis, 2025, 16(1):76
S4001	Cabozantinib S-malate	Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.	Sci Rep, 2025, 15(1):35889 bioRxiv, 2025, 2025.08.15.670608 Nat Neurosci, 2024, 10.1038/s41593-024-01604-8
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Cell Rep, 2025, 44(8):116149 Commun Med (Lond), 2025, 5(1):206 Front Cell Neurosci, 2024, 18:1441827
S1244	Amuvatinib (MP-470)	Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. It suppresses c-MET and c-RET, and is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220 Hematol Oncol, 2025, 43(5):e70131 bioRxiv, 2024, 2023.11.21.568071
S8570	CEP-40783 (RXDX-106)	CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.	UNIVERSITY OF CALIFORNIA, 2023, bioRxiv, 2023, 2023.10.20.563266 Mol Cancer Res, 2022, 20(4):542-555
S9662	UNC2025	UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. This compound also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.	iScience, 2024, 27(7):110226 Commun Biol, 2023, 6(1):916 Int J Mol Sci, 2023, 10.3390/ijms242115903
S3759	Norcantharidin	Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.	Molecular Medicine Reports, 2024, 71 Mol Med Rep, 2024, 29(5)71 Phytother Res, 2023, 10.1002/ptr.7963
S6412	Altiratinib	Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. This compound inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.	J Microbiol, 2025, 63(2):e2409001 Theranostics, 2021, 11(20):9918-9936 Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. This compound inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. It inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. This chemical also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S6764	Pamufetinib (TAS-115)	Pamufetinib (TAS-115) is a highly potent c-Met and VEGFR dual inhibitor with IC50s of 30 nM and 32 nM for recombinant VEGFR2 and recombinant MET, respectively.